<DOC>
	<DOCNO>NCT02553460</DOCNO>
	<brief_summary>The purpose study test good bad effect study drug bortezomib vorinostat give combination chemotherapy commonly use treat acute lymphoblastic leukemia ( ALL ) infant . For example , add drug could decrease number leukemia cell , could also cause additional side effect . Bortezomib vorinostat approve US Food Drug Administration ( FDA ) treat cancer adult , approve treat child leukemia . With research , plan meet following goal : PRIMARY OBJECTIVE : - Determine tolerability incorporate bortezomib vorinostat ALL chemotherapy backbone newly diagnose infant ALL . SECONDARY OBJECTIVES : - Estimate event-free survival overall survival infant ALL treat bortezomib vorinostat combination ALL chemotherapy backbone . - Measure minimal residual disease ( MRD ) positivity use flow cytometry PCR . - Compare end induction , end consolidation , end reinduction MRD level Interfant99 ( ClinicalTrials.gov registration ID number NCT00015873 ) participant outcome .</brief_summary>
	<brief_title>Total Therapy Infants With Acute Lymphoblastic Leukemia ( ALL ) I</brief_title>
	<detailed_description>Treatment consist 4 main phase : Remission Induction , Consolidation , Reinduction , Maintenance . High risk patient receive reintensification phase prior transplant first remission . REMISSION INDUCTION : Chemotherapy give attempt induce participant 's leukemia remission . Drugs give intrathecal triple drug treatment methotrexate , hydrocortisone Ara-C ( ITMHA ) ; dexamethasone ; vorinostat ; bortezomib ; PEG-asparaginase ; mitoxantrone ; cyclophosphamide ; cytarabine ; 6-mercaptopurine . CONSOLIDATION PHASE : After participant 's blood count recover Remission Induction , he/she move consolidation phase . This therapy give kill remain leukemia cell . Drugs give ITMHA , high-dose methotrexate , 6-mercaptopurine . RE-INDUCTION : This phase aim improve participant 's overall response therapy seek bring his/her leukemia remission . Drugs give ITMHA , mitoxantrone , peg-asparaginase , dexamethasone , bortezomib , vorinostat . RE-INTENSIFICATION : If participant 's maximum residual disease ( MRD ) negative consolidation , he/she receive intensification therapy , go stem cell transplant ( SCT ) ( SCT part study ) . MAINTENANCE PHASE : Participants negative MRD consolidation skip re-intensification phase proceed receive maintenance therapy keep leukemia return . Drugs give ITMHA , dexamethasone , vincristine , 6-mercaptopurine methotrexate . Each cycle drug last 28 day repeat 20 time long serious side effect .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Patient ≤ 365 day age time diagnosis . Patient newly diagnose acute lymphoblastic leukemia ( ALL ) acute undifferentiated leukemia ≥25 % blast bone marrow ( M3 ) , without extramedullary disease . Patients Tcell ALL eligible . Patients bilineage biphenotypic acute leukemia eligible , provided morphology immunophenotype predominantly lymphoid . Limited prior therapy , include systemic glucocorticoid one week less , one dose vincristine , one dose intrathecal chemotherapy . Written informed consent follow Institutional Review Board , NCI , FDA , Office Human Research Protections ( OHRP ) Guidelines . Patients prior therapy , therapy specify Inclusion Criteria . Patients mature Bcell ALL acute myelogenous ( AML ) . Patients Down syndrome . Inability unwillingness legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>365 Days</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Infants</keyword>
</DOC>